App-Quantinova.ai

Comparison of plasma ctDNA from the portal and peripheral veins of resectable CRC patients.

Xin-Xing Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparative analysis of the representative value of somatic mutation profiles derived from ctDNA and other updated lung tumor biopsy alternative in non-resectable non-small cell lung cancer patients.

Xiaozheng Kang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Mutation detection in circulating tumor DNA in stage I vs. later stage cancer samples.

Aaron Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors.

Phil Stephens - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

TOMA OS-Seq: An efficient oligo-selective sequencing solution to identify tumor-specific mutations and copy number alterations.

Yosr Bouhlal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Mutation detection in cell free DNA from healthy donors.

Anja Kammesheidt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating cancer associated macrophage-like cells in the detection of invasive breast cancer.

Daniel L Adams - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cell-free circulating tumour DNA as a tool for monitoring response to anti-EGFR therapies of mCCR.

Estela Vega - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Erbitux

Soluble human histocompatibility antigens (HLA) as potential biomarkers for early detection of non-small lung carcinoma (NSCLC).

Smriti Kanangat - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating tumor microemboli as a prognostic factor for locally advanced or metastatic solid tumors.

Marcelo Corassa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.

Collin M. Blakely - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An ultra-deep next generation sequencing method for cfDNA detection in NSCLC patients.

Yu Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Molecular detection of ROS1-rearranged circulating tumor cells (CTC) in non-small cell lung cancer (NSCLC) patients.

Man Chun Leong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Modelization of the procoagulant properties of cancer cells and the alterations of the effectiveness of the anticoagulant agents.

Aurelie Rousseau - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fondaparinux sodium

Benefits and limitations of liquid biopsy in one patients clinical trial paradigm.

Jean-Francois Laes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Near complete remission of pulmonary metastases in triple negative breast cancer (TNBC) using low-dose immune checkpoint (IC) inhibitors with high dose (HD) interleukin-2 (IL-2) and fever range hyperthermia.

Ralf Kleef - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alpha Lipoic Acid

Combining FoxP3 and Helios with GARP/LAP markers to identify expanded Treg subsets in cancer patients.

Eyad Elkord - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comparison of comprehensive genomic profiling (CGP) and hotspot next generation sequencing (NGS) assays in identifying treatment options for care of patients with metastatic cancer in in the community setting.

Ricardo H. Alvarez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical outcomes in genetically targeted cancer treatment.

John Michael Rozehnal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Frequency of actionable somatic alterations with genomic profiling: the Columbia University experience.

Adam J. Widman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts